-transparent.png){kind=logo}
The relation between characteristics known at start of therapy and response in 102 adults with refractory acute leukemia who received 4'-(9 acridinylamino)-methane-sulfon-m-anisidide (AMSA) was examined. Twenty-three (23%) of these patients attained complete remission (CR). Univariate analysis showed that the following characteristics were associated with CR: a fewer number of prior induction and maintenance regimens, a shorter time between latest relapse and AMSA therapy, the presence of Auer rods, a circulating blast cell count of less than 25,000/mm3, a marrow cellularity less than 90%, a ratio of marrow blasts and promyelocytes to more mature myeloid cells (differentiation ratio) less than 15, and a first-course AMSA dose of greater than or equal to 375 mg/m2. Some of these factors were interrelated. Multivariate analysis using logistic regression techniques was carried out to determine which of the above factors added independent prognostic information. This analysis produced a statistical model that related probability of response to the following in order of selection: Auer rod status, first-course dose, differentiation ratio, and absolute circulating blast cell count. Such a model could be useful in identifying patients with high, intermediate, or low probability of response to AMSA. AMSA could then be prescribed only for patients likely to respond while affording other patients alternate salvage programs at an earlier time.
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
July 2010,
Leukemia research,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
February 1984,
Israel journal of medical sciences,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
July 1982,
Cancer treatment reports,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
September 1950,
Nordisk medicin,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
August 1955,
Casopis lekaru ceskych,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
May 1983,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
November 1962,
Gazette medicale de France,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
September 1988,
Blood,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
March 1999,
Haematologica,
E H Estey, and
M J Keating, and
T L Smith, and
K B McCredie, and
S S Legha, and
R S Walters, and
G P Bodey, and
E J Freireich
September 1987,
Therapeutic drug monitoring,
